Phase 2 N=21 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Bone Metabolism — 34.3; 10.4 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 3 N=34 Pamidronate to Treat Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score
Phase 2 N=28 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Disorder of Bone Density and Structure, Unspecified
Primary: Change in Spine Bone Density (g/cm^2) — -0.00558 gm/cm^2 — p=0.40
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
N/A N=20 Developing a COMputerised Bone Age Tool
Bone Diseases, Developmental
Primary: Number of Participants With Observer Agreement Between Bone Age as Assessed From Left Hand and Wrist DXA Compared to Radiographs — 20 Participants
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Phase 2 N=35 Testosterone and Growth Hormone for Bone Loss in Men
Hypopituitarism · Hypogonadism · Growth Hormone Deficiency
Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless
Phase 3 N=110 Effects of Anorexia Nervosa on Bone Mass in Adolescents
Anorexia Nervosa
Primary: Percent Change in Spine Bone Density Over the Study Duration (18 Months) — 2.6; 0.3 Percent change — p=<0.05
Phase 2 N=112 A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Osteogenesis Imperfecta, Type I · Osteogenesis Imperfecta Type III · Osteogenesis Imperfecta Type IV
Primary: Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12 — 1.004; 0.993; 0.992 ratio — p=0.644
Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
N/A N=22 Prevention of Post Operative Bone Loss in Children
Osteoporosis · Cerebral Palsy · Spina Bifida
Primary: Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan — 0.043; -0.025 percent change
Phase 3 N=143 Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population — 7.592; 16.159 Percent Change — p=<0.0001
Phase 4 N=18 Bisphosphonate Therapy for Osteogenesis Imperfecta
Osteogenesis Imperfecta · Osteoporosis · Paget Disease of Bone
Primary: Bone Mineral Density — -1.3; -1.1 z-score
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
N/A N=138 Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial
Crohn Disease
Primary: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months — 0.15; 0.23 Z-score — p=0.38
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=102 A Prospective Study of Human Bone Adaptation Using a Novel in Vivo Loading Model
Bone Loss
Primary: Change in UD iBMC — 0.0049; -0.0020; 0.0252; 0.0309 g — p=0.119
N/A N=866 Dissemination of a Theory-Based Bone Health Program in Online
Osteoporosis · Health Behaviors
Primary: Changes in Osteoporosis Knowledge, Self-efficacy/Outcome Expectations for Calcium Intake and Exercise, Health Behaviors (Calcium Intake, Exercise) — 19.8; 19.3; 16.7…
Phase 3 N=16 Prospective Biomarkers of Bone Metabolism in Hemophilia A
Hemophilia · Bone Disease
Primary: Bone Biomarker Density (BMD) — -0.74; -0.16; -0.16 Z-Score
N/A N=739 Jump-In: Building Better Bones
Adolescent Development
Primary: Baseline Total Volumetric Bone Density at the Femur 4% Site — 277.25; 270.79 milligrams per cubic centimeter (mg/ccm)
N/A N=94 Bone Health in Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Primary: Bone Mineral Density in FSHD — -0.4 z-score
Phase 3 N=7,287 Intensive Glycemic Control and Skeletal Health Study
Atherosclerosis · Cardiovascular Diseases · Hypercholesterolemia
Primary: Number of Participants With at Least One Non-vertebral Fracture — 198; 189 participants — p=0.678
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
N/A N=12 Sleep Disruption Induced Impairments in Bone Formation
Healthy
Primary: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP) — 72.1; 67.4 ng/mL — p=0.53